2021-08-10| China

China Allows Trials to Evaluate Mixing and Matching of INOVIO, Sinovac Vaccines

by Tyler Chen
Share To

To quickly vaccinate the global population, several biotech companies have launched clinical trials to examine the efficacy and safety of mixing COVID-19 vaccines. So, a second shot of the same vaccine wouldn’t be necessary for the vaccination to remain effective.


Mixing a DNA and an Inactivated Vaccine

On August 9th, China allowed Inovio to conduct two clinical trials mixing its DNA vaccine, INO-4800, and the WHO-approved inactivated vaccine, Sinovac’s CoronaVac. The trials will investigate the safety, tolerability, and immunogenicity of the combination.

In fact, the mixing of INO-4800 and CoronaVac have already been examined in animal models. Results show increased levels of antigen-specific binding antibodies, neutralizing antibodies by both live-virus neutralization assay and hACE2 receptor blocking assay, and antigen-specific T cell immune responses.


INO-4800’s Clinical Progress

Currently, INO-4800 has entered the Phase 3 segment of the Phase 2/3 INNOVATE trial. The global trial will take place in countries in Latin America, Asia, and Africa. According to Phase 1 and 2 trials, INO-4800 could generate a strong CD8 T cell level against the Delta variant and induce balanced T cells and B cells immune response.

The strongest suit of INO-4800 lies in its ability to be stable at room temperature for over 1 year and at 37°C for 1 week, alleviating the cold chain requirements in transportation. Together with the anti-Delta variant activity, INO-4800 could be the primary and booster dose and able to reach every corner of the world, conducting vaccination in tougher conditions.


Mixing of Pfizer and AZ Vaccines

As for other such studies, the mixing of AstraZeneca vaccine (ChAdOx1-S, Vaxzevria) and Pfizer vaccine (BNT162b2, Comirnaty) are proven to increase neutralizing antibodies substantially compared to taking 2 doses of ChAdOx1-S. And patients only showed mild to moderate levels of adverse events, which is a positive safety profile.

© All rights reserved. Collaborate with us:
Related Post
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
Major U.S. Organization BIO Severs Ties With Member WuXi AppTec Amid U.S. Government’s Security Concerns
Saudi Arabia Reveals Grand Ambition to Become a Global Biotech Powerhouse by 2040
Oncology’s New Drugs on the Horizon (II): Radiotherapy, Radioligands & Other Therapeutic Agents
Oncology’s New Drugs on the Horizon (I): Cancer Immunotherapy and Targeted Therapy
Vertex Pharmaceuticals Makes $4.9 Billion Bet on Kidney Disease Treatment through Alpine Immune Acquisition
Bayer Signs New Partnership with Google Cloud, Joining Hands for AI Solutions for Radiologists
Pharmacogenomics (PGx) Shaping the Dynamic APAC Regions
Connecting Biotech Ecosystems: Success of Los Angeles Event Sets Stage for APAC-US Collaboration
Innovating Prostate Cancer Care: SYNC-T, Proteogenomics, and Culturally Tailored Education at AACR 2024
Scroll to Top